[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

RUA Life Sciences PLC Results of GM, TVR and Directors' Dealings

30/12/2020 11:36am

UK Regulatory (RNS & others)


Aortech (LSE:AOR)
Historical Stock Chart


From Aug 2020 to Aug 2021

Click Here for more Aortech Charts.

TIDMRUA

RNS Number : 1594K

RUA Life Sciences PLC

30 December 2020

30 December 2020

RUA Life Sciences plc

(the "Company" or the "Group")

Results of General Meeting

Total Voting Rights

Director/PDMR Dealings

RUA Life Sciences plc (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon(TM), a long-term implantable biostable polymer, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders.

Furthermore, as announced earlier today the Open Offer closed for acceptances at 11.00 a.m. on 29 December 2020 with final valid applications from Qualifying Shareholders in respect of 831,522 Open Offer Shares. Qualifying Shareholders who have validly applied for Open Offer Shares have received their full Open Offer Entitlement. Applications made under the Excess Application Facility were oversubscribed and have been scaled back pro-rata such that approximately 9.7 per cent. of the Excess Application is satisfied.

Accordingly, the Company will raise a total of approximately GBP7.0 million (before expenses) through the Placing, Subscription and Open Offer and has thus issued and allotted 5,831,522 New Ordinary Shares. An application has been made for the 5,831,522 New Ordinary Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 31 December 2020.

The net proceeds of the Placing, Subscription and Open Offer will be used by the Company primarily to fund the acceleration of the Group's surgical heart valve through to human trials, to accelerate development of the Company's TAVI valve, to scale up the Group's graft manufacture to meet anticipated demand and to allow further investment in capital equipment to assist in the scale up of the Group's capacity.

Following Admission, the Company's issued share capital will comprise 22,184,797 Ordinary Shares, of which none are held in treasury, and 4,832,778 Deferred Shares which carry no voting rights. The above figure of 22,184,797 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

 
        Resolution                 For &             Against           Withheld         Total 
                               Discretionary                                            votes 
                                                                                         cast 
                              Number       %      Number      %      Number     % 
                              of votes            of votes           of votes 
    ----------------------  ----------  ------  ----------  -----  ----------  ----  ---------- 
     Allotment of 
      Ordinary Shares 
 1    for Fundraising        3,587,593   99.19    28,968     0.80      328     0.01   3,616,889 
    ----------------------  ----------  ------  ----------  -----  ----------  ----  ---------- 
     Pre-emption 
 2    rights Fundraising     3,587,593   99.19    28,968     0.80      328     0.01   3,616,889 
    ----------------------  ----------  ------  ----------  -----  ----------  ----  ---------- 
     Allotment of 
      Ordinary Shares, 
 3    general authority      3,587,593   99.19    28,968     0.80      328     0.01   3,616,889 
    ----------------------  ----------  ------  ----------  -----  ----------  ----  ---------- 
     Pre-emption 
 4    rights                 3,586,593   99.16    28,968     0.80     1,328    0.04   3,616,889 
    ----------------------  ----------  ------  ----------  -----  ----------  ----  ---------- 
     Pre-emption 
      rights, acquisitions 
      and specified 
 5    investments            3,586,593   99.16    28,968     0.80     1,328    0.04   3,616,889 
    ----------------------  ----------  ------  ----------  -----  ----------  ----  ---------- 
 

John Ely, a Non-Executive Director of the Company and Anthea Berg, a Person Closely Associated with Geoffrey Berg, a Non-Executive Director of the Company, have subscribed for New Ordinary Shares through the Subscription as detailed below.

 
 Director/PDMR      Shares Acquired   Total Holding*    Percentage of 
                                                        Enlarged Share 
                                                           Capital* 
 John Ely                4,167            4,167             0.0% 
                   ----------------  ---------------  ---------------- 
 Geoffrey Berg**         8,333            25,018            0.1% 
                   ----------------  ---------------  ---------------- 
 

* following Admission

** Application made in the name of Anthea Berg, wife of Geoffrey Berg

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to Shareholders on 11 December 2020.

For more information please contact:

 
 
 RUA Life Sciences plc 
 Bill Brown, Chairman                          Tel: +44 (0) 77 3071 
  David Richmond, CEO                           8296 
                                                Tel: +44 (0) 78 9999 
                                                6400 
 Shore Capital (Nomad and Joint Broker) 
  Tom Griffiths/David Coaten                     Tel: +44 (0)20 7408 
                                                 4080 
  Cenkos Securities plc (Joint Broker) 
  Russell Cook/Max Gould (Corporate Finance) 
  Michael Johnson (Sales)                        Tel: +44 (0) 20 7397 
                                                 8900 
 

About RUA Life Sciences plc

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon(TM), widely accepted as being the most biostable of all long-term implantable polyurethanes.

Whether it is licensing Elast-Eon(TM), manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, the Group's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
RUA Medical :     End-to-end contract developer and manufacturer 
                   of medical devices and implantable fabric specialist. 
RUA Biomaterials  Licensor of Elast-Eon(TM) polymers to the medical 
 :                 device industry. 
RUA Vascular      Commercialisation of large bore polymer sealed 
 :                 grafts and soft tissue patches. 
RUA Structural    Development of tri leaflet polymeric heart valves. 
 Heart : 
 
 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
        ------------------------------------------------------------------------------------ 
 a.      Name                                     John Ely 
        ---------------------------------------  ------------------------------------------- 
 2       Reason for notification                  Acquisition of shares 
        ---------------------------------------  ------------------------------------------- 
 a.      Position/Status                          Non-Executive Director 
        ---------------------------------------  ------------------------------------------- 
 b.      Initial notification/                    Initial notification 
          Amendment 
        ---------------------------------------  ------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
        ------------------------------------------------------------------------------------ 
 a.      Name                                     RUA Life Sciences Plc 
        ---------------------------------------  ------------------------------------------- 
 b.      LEI                                      213800BMVB22PVOJ9Z28 
        ---------------------------------------  ------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
        ------------------------------------------------------------------------------------ 
 a.      Description of                           Ordinary shares of 5p each 
          the financial 
          instrument, type 
          of instrument 
                                                   ISIN: GB0033360586 
          Identification 
          Code 
        ---------------------------------------  ------------------------------------------- 
 b.      Nature of the                            Share purchase 
          transaction 
        ---------------------------------------  ------------------------------------------- 
 
 c.      Price(s) and volume(s)                    Price(s) per           Volume(s) 
                                                    share 
        ---------------------------------------   --------------------- 
                                                   120p                   4,167 
                                                  ---------------------  --------------- 
 
 d.      Aggregated information 
 
          - Aggregated Volume                       n/a 
 
          - Price 
        ---------------------------------------  ------------------------------------------- 
 e.      Date of the transaction                  31 December 2020 
        ---------------------------------------  ------------------------------------------- 
 f.      Place of the transaction                 London Stock Exchange 
        ---------------------------------------  ------------------------------------------- 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
        ------------------------------------------------------------------------------------ 
 a.      Name                                     Anthea Berg, PCA with Geoffrey Berg 
        ---------------------------------------  ------------------------------------------- 
 2       Reason for notification                  Acquisition of shares 
        ---------------------------------------  ------------------------------------------- 
 a.      Position/Status                          Wife of Non-Executive Director 
        ---------------------------------------  ------------------------------------------- 
 b.      Initial notification/                    Initial notification 
          Amendment 
        ---------------------------------------  ------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
        ------------------------------------------------------------------------------------ 
 a.      Name                                     RUA Life Sciences Plc 
        ---------------------------------------  ------------------------------------------- 
 b.      LEI                                      213800BMVB22PVOJ9Z28 
        ---------------------------------------  ------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
        ------------------------------------------------------------------------------------ 
 a.      Description of                           Ordinary shares of 1p each 
          the financial 
          instrument, type 
          of instrument 
                                                   ISIN: GB0033360586 
          Identification 
          Code 
        ---------------------------------------  ------------------------------------------- 
 b.      Nature of the                            Share purchase 
          transaction 
        ---------------------------------------  ------------------------------------------- 
 
 c.      Price(s) and volume(s)                    Price(s) per           Volume(s) 
                                                    share 
        ---------------------------------------   --------------------- 
                                                   120p                   8,333 
                                                  ---------------------  --------------- 
 
 d.      Aggregated information 
 
          - Aggregated Volume                       n/a 
 
          - Price 
        ---------------------------------------  ------------------------------------------- 
 e.      Date of the transaction                  31 December 2020 
        ---------------------------------------  ------------------------------------------- 
 f.      Place of the transaction                 London Stock Exchange 
        ---------------------------------------  ------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMEAFAEDDLEFFA

(END) Dow Jones Newswires

December 30, 2020 06:36 ET (11:36 GMT)

1 Year Aortech Chart

1 Year Aortech Chart

1 Month Aortech Chart

1 Month Aortech Chart
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210805 22:53:06